In re: Entresto (sacubitril/valsartan)… v. Nanjing Noratech Pharmaceutical Co., Ltd.

N OTE: This order is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
IN RE: ENTRESTO (SACUBITRIL/VALSARTAN)
-------------------------------------------------
NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant
v.
NANJING NORATECH PHARMACEUTICAL CO.,
LTD.,
Defendant-Appellee
______________________
2023-2317, 2023-2319
______________________
Appeals from the United States District Court for the
District of Delaware in Nos. 1:20-md-02930-RGA and 1:23-
cv-00401-RGA, Judge Richard G. Andrews.
______________________
ON MOTION
______________________
Before L OURIE, T ARANTO, and STOLL , Circuit Judges.
P ER CURIAM .
O R D E R
Case: 23-2317 Document: 25 Page: 1 Filed: 03/11/2025

-- 1 of 2 --

IN RE: ENTRESTO ( SACUBITRIL/ VALSARTAN) 2
Upon consideration of appellant’s motion to stay the fi-
nal judgment pending appeal, appellee’s motion to dismiss,
the parties’ joint statement that if the invalidity judgment
in Appeal No. 2023-2218 “is not affirmed,” “the judgment
in this case should be vacated and the case remanded for
further proceedings,” ECF No. 9 at 3, and this court’s re-
cent decisions and orders in Appeal No. 2023-2218 revers-
ing the relevant aspect of the judgment and enjoining the
defendants in that case from launching their generic drug
until issuance of mandate in that appeal,
I T I S O RDERED T HAT :
(1) The district court’s judgment is vacated and the
cases remanded to the district court for further proceed-
ings.
(2) The district court’s judgment is stayed until issu-
ance of mandate in Appeal Nos. 2023-2317, 2023-2319.
(3) Any pending motion otherwise is denied.
(4) Each party shall bear its own costs.
March 11, 2025
Date
F OR THE COURT
Case: 23-2317 Document: 25 Page: 2 Filed: 03/11/2025

-- 2 of 2 --